Two Sigma Advisers’s AbbVie ABBV Stock Holding History

Two Sigma Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-7,000	Closed	-$404K	–	2396
2014 Q3	$404K	Sell	7,000 -16,000	-70%	-$888K	﹤0.01%	1665
2014 Q2	$1.3M	Buy	+23,000	New	+$1.21M	0.01%	1029
2014 Q1	–	Sell	-66,400	Closed	-$3.51M	–	2217
2013 Q4	$3.51M	Sell	66,400 -52,600	-44%	-$2.59M	0.03%	491
2013 Q3	$5.32M	Buy	119,000 +7,200	+6%	+$319K	0.06%	313
2013 Q2	$4.62M	Buy	+111,800	New	+$4.89M	0.07%	261

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Two Sigma Advisers's ABBV Position: Q1 2026 in Review

Two Sigma Advisers sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 165,444 shares — an estimated $37.8M sold.

Two Sigma Advisers first reported a position in ABBV in Q2 2013 and held it in 48 quarters. The position peaked at $506M in Q4 2019. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Two Sigma Advisers reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 165,444 AbbVie shares in Q1 2026, an estimated $37.8M.
Two Sigma Advisers first reported a position in AbbVie in Q2 2013 and held it in 48 quarters.
Two Sigma Advisers's AbbVie position peaked at $506M in Q4 2019.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.